BIOMARKERS FOR TREATMENT WITH ANTI-TUBULIN CHEMOTHERAPEUTIC COMPOUNDS

摘要

Provided herein are methods of monitoring whether a patient with a hyperproliferative disorder will respond to treatment with an anti-tubulin chemotherapeutic agent and methods of optimizing therapeutic efficacy of an anti-tubulin chemotherapeutic agent, wherein the biomarkers used in such methods are Mcl-1 and/or FBW7.